"In the pharmaceutical sector, we continue adding new products to our portfolio to service the private and government sector in the synthesis, APIs and excipients fields."
"We continue with our strategic plan to take advantage of the nearshoring trend. We recently established a tolling arrangement to produce goods for export to the US and, further down the line, for the domestic and North LATAM markets."
"In the next 12 months, we aim to solidify our presence in Mexico. After that, we will assess whether to expand into Colombia or Brazil with physical offices and warehouses."
"We are witnessing significant growth driven by the expansion of our clients here, alongside a wave of new companies investing and expanding under the framework of nearshoring."
"Our challenge lies in becoming more efficient in waste collection, using technology and improving logistics to offer PCR as an environmentally sustainable yet economically viable solution."
"Nearshoring is nothing new to Mexico, where for many years Tier 1 and Tier 2 companies, especially in the automotive and aerospace sectors, established a presence in Mexico."
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.